etoposide has been researched along with Carcinoma, Anaplastic in 185 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (14.59) | 18.7374 |
| 1990's | 69 (37.30) | 18.2507 |
| 2000's | 54 (29.19) | 29.6817 |
| 2010's | 29 (15.68) | 24.3611 |
| 2020's | 6 (3.24) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, DT; Clement, JJ; Klein, LL; McDonald, EJ; Plattner, JJ; Yeung, CM | 1 |
| Costa, NE; Deveau, AM; Joshi, EM; Macdonald, TL | 1 |
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZH; Huang, ZS; Li, D; Ou, JB; Ou, TM; Shen, LL; Tan, JH; Wu, WB | 1 |
| Bison, B; Diez, B; Fuller, GN; Garami, M; Kebudi, R; Kordes, UR; Kutluk, T; Sterba, J; Timmermann, B; Van Gool, SW; Wolff, JE | 1 |
| Ballenberger, M; Harshan, M; Indaram, M; Machnicki, S; Mina, B; Novoselac, AV; Singh, A; Vojnic, M | 1 |
| Ben-Ami, T; Bisogno, G; Bolle, S; Brecht, IB; DuBois, SG; Ferrari, A; Fichera, G; Flaadt, T; Fox, E; Fresneau, B; Lauer, UM; Lemelle, L; Moya-Plana, A; Orbach, D; Rodriguez-Galindo, C; Roganovic, J; Schneider, DT; Surun, A; Timmermann, B; Vokuhl, C | 1 |
| Carlos, R; Díaz Molina, JP; Paes de Almeida, O; Sánchez-Romero, C | 1 |
| Chang, JS; Pan, M | 1 |
| Al-Haideri, M; Duan, M; Mahal, A; Mai, S; Mohammed, B; Tao, H; Zhu, Q; Zhu, Y | 1 |
| Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K; Tanaka, Y; Yamamoto, H; Yoshitake, R | 1 |
| Al-Jiffry, BO; Al-Malki, O | 1 |
| Buiga, R; Irimie, A; Kontogeorgos, G; Piciu, A; Piciu, D | 1 |
| Bezjak, A; Blackmon, S; Choi, N; Fidias, P; Keshavjee, S; Korst, RJ; Liu, G; Marx, A; Mock, S; Rutledge, JR; Wright, C | 1 |
| Mulchandani, M; Sankaranarayanan, A; Tirupati, S | 1 |
| Garami, M; Hauser, P; Pócza, T; Schuler, D; Vancsó, I | 1 |
| Brtnický, T; Fialová, A; Laštovička, J; Rob, L; Špíšek, R | 1 |
| Brown, RJ; Dhall, G; Finlay, JL; Gardner, SL; Ginn, KF; Khatua, S; Yankelevich, M; Yildiz, VO; Zaky, W | 1 |
| Iwafuchi, H; Iwama, J; Kiyotani, C; Matsuoka, K; Morota, N; Ogiwara, H; Terashima, K | 1 |
| Bouffet, E; Coluccia, D; Hawkins, C; Kamaly-Asl, I; Kulkarni, AV; Lafay-Cousin, L; Ramaswamy, V; Remke, M; Rutka, JT; Schneider, C; Tabori, U; Taylor, MD | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Bowers, SP; Gibson, S; Reed, N; Spiliopoulou, P; White, J | 1 |
| Almadana Pacheco, V; Benito Bernáldez, C; Romero Muñoz, C | 1 |
| Alvarez, MJ; Ambesi-Impiombato, A; Andrews, SJ; Califano, A; Dela Cruz, FS; Diolaiti, D; Forouhar, F; Glade Bender, JL; Kung, AL; Mansukhani, MM; Marks, LJ; Mitchell, CM; Modzelewski, B; Nagy, PL; Rainey, AR; Turk, AT; Yamashiro, DJ | 1 |
| Abdalla, B; Alfaar, AS; Awad, M; Rashed, WM; Taha, H; Zekri, W | 1 |
| Hirama, M; Isonishi, S; Kiyokawa, T; Kunito, S; Ochiai, K; Ogura, A; Suzuki, M; Tachibana, T; Tanaka, T | 1 |
| Bernard, C; Grushka, JR; Laberge, JM; Mueller, C; Nguyen, VH; Puligandla, PS; Roessingh, Ade B; Ryckman, J; St Vil, D; Walton, JM | 1 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Arslan, C; Kilickap, S | 1 |
| Fabian, I; Halperin, D; Priel, E; Reuveni, D; Shalit, I | 1 |
| Ben-Shachar, I; Benshushan, A; Kogan, L; Lavie, M; Mejia-Gomez, J; Shushan, A | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Couvelard, A; Dokmak, S; Hammel, P; Hentic, O; Lévy, P; Maire, F; O'Toole, D; Rebours, V; Ruszniewski, P; Sauvanet, A; Zappa, M | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Agatsuma, T; Hanaoka, M; Ito, M; Kanda, S; Koizumi, T; Kubo, K; Urushihata, K; Yamamoto, H | 1 |
| Batsuren, D; Jho, EH; Kang, JH; Kang, K; Kim, M; Nho, CW; Oh, SH; Park, KH; Tunsag, J; Yun, JH | 1 |
| Chan, AW; Cianchetti, M; Deschler, DG; Liebsch, NJ; Varvares, MA; Wang, JJ | 1 |
| Bernasconi, S; Bono, F; Broggini, M; Damia, G; Fruscio, R; Ganzinelli, M; Mangioni, C; Perego, P; Ricci, F; Russo, G; Signorelli, M | 1 |
| Guirado Torrecillas, L; Hernández Contreras, ME; Rosa Salazar, V | 1 |
| Bozko, P; Larsen, AK; Raymond, E; Skladanowski, A | 1 |
| Miao, L; Wang, Y; Wu, M; Yi, P | 1 |
| Chuang, TC; Kao, MC; Law, SL; Lee, YJ; Li, JW; Lin, YS; Liu, JY; Wang, V | 1 |
| Goto, K; Ishii, G; Kakinuma, R; Kubota, K; Nagai, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Suga, M; Yoh, K | 1 |
| Abad, A; Balaña, C; Cirauqui, B; Font, A; Manzano, JL; Mate, JL; Moreno, I; Rosell, R | 1 |
| Chen, F; Chen, YQ; Huang, YJ; Ji, Y; Shi, DL; Su, WJ; Wu, Q; Zhang, MQ; Zheng, ZH | 1 |
| PROPST, A | 1 |
| Becker, K; Böttcher, K; Busch, R; Fink, U; Höfler, H; Mueller, JD; Ott, K; Schulmacher, C; Siewert, JR | 1 |
| El-Deiry, WS; Wang, S | 1 |
| Nussey, F; Seckl, J; Smyth, J | 1 |
| Bartling, B; Lewensohn, R; Zhivotovsky, B | 1 |
| Buller, RE; Geisler, JP; Lush, R; Sanders, L; Shahin, MS; Sood, AK; Sorosky, JI; Sullivan, D | 1 |
| Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Obu, M; Shinoura, H; Takashima, I | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Ballard, ET; Dickens, DS; Dothage, JA; Heideman, RL; Jubinsky, PT | 1 |
| Kobayashi, S | 1 |
| Ambrogi, MC; Angeletti, CA; Basolo, F; Duranti, L; Fontanini, G; Lucchi, M; Mussi, A | 1 |
| Baehring, JM; Duncan, C; Kim, J; Ogle, E | 1 |
| Angeli, A; Berruti, A; Dogliotti, L; Gorzegno, G; Paccotti, P; Porpiglia, F; Sperone, P; Terzolo, M | 1 |
| Chan, JK; Chow, SM; Ho, CM; Law, SC; Tang, DL; Tse, LL | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Cicconetti, F; Franchi, F; Iascone, C; Ielapi, T; Nigita, G; Pastore, C; Seminara, P | 1 |
| Chen, A; Ding, F; Liu, Z; Luo, A; Ren, S; Yu, Z; Zhang, L; Zhang, S | 1 |
| Ge, W; Li, JH; Wu, YG; Xu, XM; Yuan, GJ; Zhou, ZY | 1 |
| Cho, YH; Hah, JH; Heo, DS; Kim, DW; Kim, KH; Lee, SH; Rhee, CS; Sung, MW; Wu, HG | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Antonelli, A; Barani, L; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Marchetti, I; Materazzi, G; Miccoli, P | 1 |
| Kimura, F; Miyazaki, M; Ohtsuka, M; Seki, N; Shimizu, H; Sugimoto, T; Washiro, M; Yoshidome, H | 1 |
| Balta, Z; Büttner, R; Fischer, HP; Hirner, A; Sauerbruch, T | 1 |
| Berdel, WE; Diehl, V; Graubner, M; Gropp, C; Klippstein, T; Mende, S; Mitrou, PS | 1 |
| Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Mermillod, B | 1 |
| Aisner, J; Fuks, JZ; Levitt, M; Ostrow, S; Schipper, H; Van Echo, DA; Wiernik, PH | 1 |
| Cvitkovic, E; Golbey, RB; Kelsen, DP; Kurtz, R; Lieberman, P; Weston, E | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, R; Kaplan, S; Obrecht, JP; Sonntag, R; Weber, W | 1 |
| Eguchi, K; Fukuda, M; Kasai, T; Kurata, T; Ohe, Y; Oshita, F; Saijo, N; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Hop, WC; Planting, AS; Stoter, G; van der Gaast, A; Verweij, J | 1 |
| Belldegrun, A; Bonavida, B; Borsellino, N | 1 |
| Fujie, M; Fujishiro, S; Gotoh, J; Kobayashi, H; Shinohara, H; Terao, T | 1 |
| Burgess, MA | 1 |
| Crown, J; Gilewski, T; Hamilton, N; Harrison, M; Hudis, C; Kritz, A; Moore, M; Reich, L; Schneider, J; Vahdat, L | 1 |
| Ben-Baruch, G; Brenner, H; Menczer, J; Rizel, S | 2 |
| Comella, G; Comella, P; Conforti, S; Frasci, G; Mastrantonio, P; Persico, G; Zullo, F | 1 |
| Bosl, GJ; Chaganti, RS; Mazumdar, M; Motzer, RJ; Reuter, VE; Rodriguez, E | 1 |
| Fujimoto, Y; Ito, K; Itoyama, S; Onodera, M; Shimaoka, K; Sugawara, I; Watanabe, M; Yamashita, T | 1 |
| Braly, PD; Howell, SB; Kim, S; Kirmani, S; McClay, EF; McClay, ME; Plaxe, SC; Wilgus, L | 1 |
| Iigo, M; Moriyama, M; Tsuda, H | 1 |
| Fanning, J; Hilgers, RD; Hutson, E | 1 |
| Braly, PS; Cates, C; Howell, SB; Kim, S; Kirmani, S; McClay, EF; Plaxe, SC; Saltzstein, SL | 1 |
| Hoskins, PJ; Swenerton, KD | 1 |
| de Campos, ES; Harris, M; Menasce, LP; Radford, J; Thatcher, N | 1 |
| Cavalli, F; Colombo, N; D'Incalci, M; Mangioni, C; Marzola, M; Pagani, O; Sessa, C; Zucchetti, M | 1 |
| Arakawa, H; Iguchi, T; Kurama, M; Mano, E; Nakagawa, S; Okura, A; Tanaka, N; Yoshinari, T | 1 |
| Cheong, SK; Kim, JS; Kim, YH; Lee, JD; Park, JS; Shin, SW | 1 |
| Lazo, JS; Rusnak, JM | 1 |
| Breuer, N; Eigler, FW; Fett, W; Fink, U; Makoski, HB; Molls, M; Niebel, W; Sack, H; Schmidt, U; Seeber, S; Siewert, JR; Stahl, M; Stuschke, M; Walz, MK; Wilke, H | 1 |
| Robinson, E; Shpendler, M; Zidan, J | 1 |
| Kato, J; Yasumizu, T | 1 |
| Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P | 1 |
| Effenbein, GJ; Fields, KK; Perkins, JB | 1 |
| Asaga, T; Kawahara, S; Osawa, Y; Yanoma, S; Yoshida, A | 1 |
| Clynes, M; Dolan, E; Heenan, M; Kavanagh, K; Maher, M; Moriarty, M; O'Neill, P; Redmond, A | 1 |
| Basu, A; Saijo, N; Weixel, K | 1 |
| Fraley, EE; Kennedy, BJ; Torkelson, JL | 1 |
| Hoskins, PJ; Lee, N; McMurtrie, EM; Pike, JA; Swenerton, KD | 1 |
| Berenson, RJ; Chow, W; Doroshow, JH; Forman, SJ; Hamasaki, V; Leong, L; Margolin, K; Molina, A; Morgan, R; Nowicki, B; Odom-Maryon, T; Raschko, J; Shibata, S; Sniecinski, I; Somlo, G; Tetef, M | 1 |
| Barakat, RR; Brown, C; Curtin, JP; Fennelly, D; Pizzuto, F; Venkatraman, ES | 1 |
| Satake, S; Sugawara, I; Takami, H; Watanabe, M | 1 |
| Erland, JB; Greco, FA; Hainsworth, JD; Kalman, LA; Schreeder, MT | 1 |
| Athanassiou, A; Dimitriades, M; Kostopoulou, M; Mylonakis, A; Papadopoulou, M; Pectasides, D; Triantafillis, D; Varthalitis, J | 1 |
| Boonstra, H; de Bruijn, HW; de Jong, RS; de Vries, EG; Hofstra, LS; Mulder, NH; Willemse, PH | 1 |
| Tsutsui, K | 1 |
| Greco, FA; Hainsworth, JD | 3 |
| Blessing, JA; Homesley, HD; Mayer, AR; Rose, PG | 1 |
| Baudin, E; Bonacci, R; Bonnay, M; Cailleux, AF; Emy, P; Gigliotti, A; Nakib, I; Schlumberger, M; Wion-Barbot, N | 1 |
| Ikeda, M; Ishii, H; Ito, R; Kosakamoto, H; Nakanishi, Y; Nakasuka, H; Okada, S; Okusaka, T; Sakamoto, M; Yoshimori, M | 1 |
| Matsumoto, K; Mishima, M; Nakagawa, S; Onda, T; Taketani, Y; Yamada, M; Yasugi, T; Yoshikawa, H | 1 |
| Feller, N; Hoekman, K; Kuiper, CM; Linn, SC; Pinedo, HM; Popp-Snijders, C; Verheul, HM; Wolthers, BG | 1 |
| Chikazawa, H; Fujimoto, S | 1 |
| Hennequin, C; Maylin, C | 1 |
| Dressler, V; Müller, G; Sühnel, J | 1 |
| Asano, T; Gunji, Y; Isono, K; Kimura, M; Koide, Y; Matsubara, H; Ochiai, T; Sakiyama, S; Sugaya, M; Tagawa, M; Takegana, K | 1 |
| Beijnen, JH; de Wit, R; Lieverst, J; Nannan Panday, VR; Rosing, H; Schellens, JH; Schornagel, JH; Schot, M; ten Bokkel Huinink, WW | 1 |
| de Mulder, PH; de Wit, R; Louwerens, M; Rodenhuis, S; Schornagel, J; Verweij, J | 1 |
| Berkowitz, R; Cannistra, SA; Kim, Y; Matulonis, U; Niloff, J; Quartulli, M; Seiden, M; Tung, N | 1 |
| De Laroche, G; Garnier, JF; Jacquin, JP; Pichon, A; Roques, B | 1 |
| Aleman, A; Anderlini, P; Bast, RC; Bevers, M; Bodurka-Bevers, D; Boyer, J; Burke, T; Champlin, RE; Donato, ML; Freedman, R; Gajewski, JG; Gershenson, D; Giralt, S; Ippoliti, C; Korbling, M; Lauppe, J; Levenback, C; Molldrem, J; Ueno, N; Wharton, JT; Wolf, J | 1 |
| Aref, IM; Cross, PW; Gertler, SZ; Grimard, LJ; Hanson, J; Huan, SD; Malik, ST; St Cyr, DA; Stewart, DJ; Tomiak, EM; Verma, S; Yau, JC | 1 |
| Iino, K; Oki, Y; Sasano, H | 1 |
| Aikou, T; Akiyama, S; Furukawa, T; Ikeda, R; Kitazono, M; Nagayama, S; Okumura, H; Seto, K; Sumizawa, T | 1 |
| Dowell, JE; Garrett, AM; Hande, KR; Johnson, DH; Shyr, Y | 1 |
| Berner, A; Berner, J; Pasz, S; Piekarski, J; Tenderenda, M | 1 |
| Kołodziejczyk, P; Kulig, J; Popiela, T | 1 |
| Lasset, C; Merrouche, Y; Negrier, S; Peaud, PY; Rebattu, P; Trillet-Lenoir, V; Voog, E | 1 |
| Chen, LT; Huang, TS; Lee, CC; Shu, CH; Whang-Peng, J | 1 |
| Becker, K; Busch, R; Dittler, HJ; Fink, U; Mueller, J; Schuhmacher, CP; Siewert, JR | 1 |
| Arlt, A; Breitenbroich, M; Fölsch, UR; Kalthoff, H; Schäfer, H; Schmidt, WE; Vorndamm, J | 1 |
| Munshi, HG; Pienta, KJ; Smith, DC | 1 |
| Fojo, T; Kunishio, K; Matsumoto, Y; Nagao, S; Takano, H | 2 |
| Dunkern, T; Engels, IH; Jänicke, RU; Kaina, B; Porter, AG; Schulze-Osthoff, K | 1 |
| Fojo, T; Matsumoto, Y; Nagao, S; Takano, H | 1 |
| Brady, HR; Coffey, RN; Fitzpatrick, JM; Hegarty, PK; O'Keane, C; Watson, CL; Watson, RW; Wolohan, L | 1 |
| Alvarnas, J; Chow, W; Doroshow, JH; Forman, S; Hamasaki, V; Leong, L; Longmate, J; Margolin, K; McGonigle, K; McNamara, M; Morgan, RJ; Raschko, J; Schriber, J; Shibata, S; Somlo, G; Vasilev, S; Yen, Y | 1 |
| Bergman, S; Creager, AJ; Geisinger, KR | 1 |
| Beckmann, C; Flury, R; Frei, P; Holdener, E; Jungi, WF; Senn, HJ | 1 |
| Brunner, KW; Cavalli, F; Jungi, F; Senn, HJ; Sonntag, RW | 1 |
| Arnold, AM | 1 |
| Band, PR; Connors, JM; Fetherstonhaugh, EM; Goldie, JH; Knowling, MA; Osoba, D | 1 |
| Greco, FA; Hainsworth, JD; Johnson, DH | 3 |
| Almadrones, L; Barakat, R; Curtin, J; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S | 1 |
| Ajani, JA; Dumas, P | 1 |
| Hagiwara, A; Ito, M; Lee, M; Muranishi, S; Sakakura, C; Sasabe, T; Shoubayashi, S; Takahashi, T; Tashima, S | 1 |
| Feun, LG; Gray, K; Loo, TL; Lu, K; Savaraj, N; Wang, C | 1 |
| Eden, OB; Shaw, MP | 1 |
| Carlson, RW; Dorfman, RF; Sikic, BI | 1 |
| Henzen-Logmans, SC; Rodenburg, CJ; Stoter, G; van der Gaast, A; Verweij, J | 1 |
| Kvols, LK; Moertel, CG; O'Connell, MJ; Rubin, J | 1 |
| Kredentser, DC | 1 |
| Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C | 1 |
| Beauduin, M; Bosly, A; Duprez, P; Humblet, Y; Majois, F; Prignot, J; Schallier, D; Symann, M; Weynants, P | 1 |
| Goel, R; Horton, MC; Howell, SB; Kim, S; Kirmani, S; Lucas, WE; McVey, L; Morris, J; Weiss, RJ; Zimm, S | 1 |
| Kaern, J; Tropé, C; Vergote, I; Vossli, S | 1 |
| Evans, WK; Osoba, D; Rusthoven, JJ; Shepherd, FA; Turnbull, KA | 1 |
| Harmer, C; Hoskin, PJ | 1 |
| Daghistani, D; Davis, J; Toledano, S | 1 |
| Effenberger, T; Henne-Bruns, D; Kremer, B; Weh, HJ | 1 |
| Athanassiou, AE; Bafaloukos, D; Barbounis, V; Dimitriadis, M; Pectasides, D; Varthalitis, I | 1 |
| Cummings, J; Cunningham, D; Forrest, GJ; McTaggart, L; Soukop, M; Stuart, JF | 1 |
| Cohen, CJ; Dottino, PR; Goodman, HM; Kredentser, D; Rosenberg, M | 1 |
| Blaive, B; Carles, P; Clary, C; Dongay, G; Guerin, JC; Kleisbauer, JP; Orehek, J; Poirier, R; Saretto, S; Vesco, D | 1 |
| Bell, DR; Campbell, JC; Harnett, PR; Hillcoat, BL; Levi, JA; Rome, RM; Tattersall, MH; Woods, RL | 1 |
| Chambers, JT; Chambers, SK; Kohorn, EI; Schwartz, PE | 1 |
| Beecham, J; Blessing, JA; DiSaia, PJ; Slayton, RE | 1 |
| Bugat, R; Canal, P; Carton, M; Michel, C; Soula, G | 1 |
| Greco, FA; Johnson, DH | 1 |
| Lele, SB; Malfetano, J; Piver, MS | 1 |
| Oliver, RT | 1 |
| Birch, R; Enas, G; Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Porter, LL; Wolff, SN | 1 |
| Bishop, JF; Campbell, JJ; Day, A; Hillcoat, BL; Pepperell, R; Quinn, MA | 1 |
11 review(s) available for etoposide and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Neuroendocrine small cell rectal cancer metastasizing to the liver: a unique treatment strategy, case report, and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Rectal Neoplasms; Review Literature as Topic; Somatostatin; Tomography, X-Ray Computed | 2013 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Child; Child, Preschool; Choristoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Diagnostic Errors; Doxorubicin; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Pyrazoles; Radiography; Sulfonamides; Teratoma; Thalidomide; Thymus Gland; Thyroid Neoplasms; Thyroidectomy | 2009 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Adrenal cortical carcinoma: the role of adjuvant postoperative chemotherapy.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Humans; Mitotane; Randomized Controlled Trials as Topic; Survival Rate; Texas | 1995 |
[Diagnosis and therapy of undifferentiated thyroid neoplasms; chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Survival Rate; Thyroid Neoplasms; Ultrasonography | 1997 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Nutritional Support; Radiation-Sensitizing Agents; Rectal Neoplasms | 1999 |
Germ cell neoplasms and other malignancies of the mediastinum.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bleomycin; Carcinoma; Child; Cisplatin; Combined Modality Therapy; Etoposide; Genetic Predisposition to Disease; Germinoma; Hematologic Neoplasms; Humans; Incidence; Klinefelter Syndrome; Lymphoma, Non-Hodgkin; Mediastinal Neoplasms; Neoplasm Staging; Neoplasms, Multiple Primary; Neoplasms, Nerve Tissue; Radiotherapy, Adjuvant; Seminoma; Treatment Outcome | 2001 |
Podophyllotoxin derivative VP 16-213.
Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma | 1979 |
Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Humans; Male; Neoplasm Metastasis; Remission Induction; Thymus Neoplasms; Vinblastine | 1990 |
The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Etoposide; Humans; Neoplasms, Unknown Primary | 1991 |
45 trial(s) available for etoposide and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Invasiveness; North America; Pilot Projects; Postoperative Complications; Prospective Studies; Radiotherapy Dosage; Thymectomy; Thymoma; Thymus Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary | 2003 |
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chromatography, High Pressure Liquid; Disease Progression; DNA; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Time Factors; Topotecan; Treatment Outcome | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Etoposide; Female; Humans; Male; Middle Aged; Mitomycin | 2007 |
[Cisplatin, vindesine and VP 16-213 in the treatment of inoperable non-small cell bronchial carcinoma. A clinical phase II study].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vinblastine; Vindesine | 1984 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Random Allocation | 1983 |
Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte granulocyte colony-stimulating factor support. Chemotherapy Committee, The Japanese Society of Thyroid Surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Peplomycin; Pilot Projects; Survival Rate; Thyroid Neoplasms; Thyroidectomy | 1995 |
Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Outcome | 1995 |
Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Prognosis; Remission Induction | 1995 |
Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms | 1995 |
A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Parenteral; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1995 |
A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prospective Studies; Remission Induction; Survival Analysis | 1994 |
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma; Drug Resistance; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Treatment Outcome | 1994 |
Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Unknown Primary; Retrospective Studies; Vincristine | 1994 |
Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diarrhea; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Stomatitis; Survival Rate; Tegafur; Vomiting | 1996 |
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Preoperative Care; Survival Analysis; Treatment Failure | 1996 |
Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Remission Induction; Uterine Neoplasms | 1995 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Middle Aged; Nausea; Remission Induction; Stomach Neoplasms; Survival Rate; Tegafur; Vomiting | 1996 |
Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carboplatin; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Retrospective Studies; Survival Rate; Transplantation, Autologous | 1996 |
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Analysis | 1997 |
Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carcinoma; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms | 1997 |
One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome | 1997 |
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds | 1998 |
Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Mitotane; Treatment Outcome | 1998 |
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Paclitaxel | 1999 |
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Germinoma; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Testicular Neoplasms | 1999 |
Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carcinoma; Combined Modality Therapy; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Recombinant Proteins; Transplantation, Autologous | 2000 |
A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Risk Factors; Survival Analysis | 2000 |
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2001 |
The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pilot Projects; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate | 2000 |
Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Analysis | 2000 |
Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Estramustine; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2001 |
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Ovariectomy; Survival Analysis; Transplantation, Autologous; Treatment Failure; Treatment Outcome | 2001 |
VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
Topics: Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin | 1978 |
Podophyllotoxin derivative VP 16-213.
Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma | 1979 |
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Salvage Therapy; Survival Rate | 1992 |
Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms | 1992 |
Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Humans; Male; Neoplasm Metastasis; Remission Induction; Thymus Neoplasms; Vinblastine | 1990 |
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Fluorouracil; Humans; Middle Aged; Neoplasms, Unknown Primary; Remission Induction; Survival Rate | 1991 |
Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Carcinoma; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms | 1987 |
132 other study(ies) available for etoposide and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Synthesis and antitumor activity of structural analogues of the epipodophyllotoxins.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Chemical Phenomena; Chemistry; Colonic Neoplasms; Etoposide; Humans; Indans; Leukemia P388; Lung Neoplasms; Mice; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship; Tumor Cells, Cultured | 1991 |
Synthesis of diketopiperazine-based carboline homodimers and in vitro growth inhibition of human carcinomas.
Topics: Carbolines; Carcinoma; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Diketopiperazines; Dimerization; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2008 |
Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Lung Neoplasms; Naphthoquinones; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Plasmids; Pyrans; Quinones; Sesquiterpenes; Structure-Activity Relationship; Telomerase; Topoisomerase Inhibitors | 2011 |
Final results of the Choroid Plexus Tumor study CPT-SIOP-2000.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Choroid Plexus Neoplasms; Etoposide; Humans; Randomized Controlled Trials as Topic; Registries; Treatment Outcome; Vincristine | 2022 |
A 33-Year-Old Man With Chest Pain.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma; Etoposide; Fatal Outcome; Gene Rearrangement; Humans; Liver Failure; Liver Neoplasms; Lung Neoplasms; Lymphadenopathy; Male; Neoplasm Proteins; Nuclear Proteins; Positron-Emission Tomography; Tomography, X-Ray Computed; Transcription Factors; Tumor Lysis Syndrome | 2022 |
NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Child; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Male; Neoadjuvant Therapy; Prospective Studies; Retrospective Studies; Vincristine; Young Adult | 2023 |
Pediatric nasal NK/T-cell lymphoma microscopically mimicking carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Chemoradiotherapy; Dexamethasone; Diagnosis, Differential; Etoposide; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Male; Nose; Nose Neoplasms; Skin Neoplasms | 2020 |
Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Remission Induction | 2020 |
Synthesis and antitumor activity of new tetrahydrocurcumin derivatives
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Copper; Curcumin; Drug Screening Assays, Antitumor; Etoposide; Humans; Molecular Structure; Structure-Activity Relationship | 2022 |
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Dog Diseases; Dogs; Etoposide; Female; Mammary Neoplasms, Animal; Melanoma; Mice; Neoplasms, Experimental; Osteosarcoma; Topoisomerase Inhibitors | 2017 |
Highly aggressive pathology of non-functional parathyroid carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma; Etoposide; Female; Humans; Middle Aged; Parathyroid Neoplasms; Parathyroidectomy; Treatment Outcome | 2013 |
Clozapine, cancer chemotherapy and neutropenia - dilemmas in management.
Topics: Adult; Antineoplastic Agents; Antipsychotic Agents; Bleomycin; Breast Neoplasms; Carcinoma; Cisplatin; Clozapine; Etoposide; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Schizophrenia; Seminoma; Testicular Neoplasms | 2013 |
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow; Brain Neoplasms; Brain Stem Neoplasms; Carcinoma; Celecoxib; Cerebellar Neoplasms; Child; Child, Preschool; Choroid Plexus Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Ependymoma; Etoposide; Female; Humans; Hungary; Ischemic Attack, Transient; Male; Medulloblastoma; Neuroectodermal Tumors, Primitive; Optic Nerve Glioma; Pyrazoles; Quality of Life; Retrospective Studies; Sulfonamides; Thalidomide; Treatment Outcome | 2013 |
Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Blood Circulation; Carcinoma; Cyclophosphamide; Etoposide; Female; Humans; Immunophenotyping; Middle Aged; Monitoring, Immunologic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Sensitivity and Specificity; T-Lymphocytes, Regulatory; Treatment Outcome | 2015 |
Choroid plexus carcinoma in children: the Head Start experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma; Chemoradiotherapy; Child, Preschool; Choroid Plexus Neoplasms; Cisplatin; Cranial Irradiation; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; International Agencies; Male; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Vincristine | 2015 |
Neoadjuvant chemotherapy for brain tumors in infants and young children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Carcinoma, Embryonal; Child; Child, Preschool; Choroid Plexus Neoplasms; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Ependymoma; Etoposide; Female; Glioblastoma; Humans; Infant; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neuroectodermal Tumors, Primitive; Retrospective Studies; Rhabdoid Tumor; Second-Look Surgery; Treatment Outcome; Vincristine | 2015 |
Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Child, Preschool; Choroid Plexus Neoplasms; Etoposide; Female; Humans; Ifosfamide; Male; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis | 2015 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics?
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cancer Care Facilities; Carcinoma; Carcinoma, Papillary; Cisplatin; Etoposide; Humans; Male; Medical Records; Neoplasms, Second Primary; PTEN Phosphohydrolase; Scotland; Tertiary Care Centers; Testicular Neoplasms; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
NUT midline carcinoma of the lung, a rare form of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chromosomes, Human, Pair 15; Cisplatin; Etoposide; Fatal Outcome; Humans; Lung Neoplasms; Male; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins; Palliative Care; Pneumonectomy; Positron-Emission Tomography; Proteins; Tomography, X-Ray Computed; Translocation, Genetic; Young Adult | 2016 |
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Etoposide; Fatal Outcome; Genomics; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Paclitaxel; Rare Diseases; Scalp; Xenograft Model Antitumor Assays | 2016 |
Nonfunctioning Adrenocortical Carcinoma in Pediatric Acute Lymphoblastic Leukemia: A Case Report of a Rare Multiple Primaries Combination.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Fatal Outcome; Humans; Language Development Disorders; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Nephrectomy; Pneumonectomy; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Rectum; Treatment Outcome | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Paclitaxel; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2010 |
Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Carcinoma; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cytotoxins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; Etoposide; Fluoroquinolones; HT29 Cells; Humans; Moxifloxacin; Quinolines; Topoisomerase II Inhibitors | 2010 |
Fertility in women after surgical treatment of nonepithelial ovarian tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fertility; Humans; Hysterectomy; Infertility, Female; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovariectomy; Retrospective Studies; Young Adult | 2010 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Digestive System Neoplasms; Etoposide; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Retrospective Studies | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neutropenia; Retrospective Studies; Thymus Neoplasms; Treatment Outcome; Vincristine | 2011 |
A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Drugs, Investigational; Etoposide; HCT116 Cells; Hematologic Diseases; Hep G2 Cells; Humans; Male; Mice; Mice, Nude; Models, Biological; Naphthalenes; Topoisomerase Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Risk of sinonasal-cutaneous fistula after treatment for advanced sinonasal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cutaneous Fistula; Etoposide; Female; Fistula; Follow-Up Studies; Humans; Male; Middle Aged; Nasal Cavity; Neuroectodermal Tumors; Paranasal Sinus Diseases; Paranasal Sinus Neoplasms; Paranasal Sinuses; Postoperative Complications; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Sarcoma; Young Adult | 2012 |
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Cell Differentiation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Fluorescent Antibody Technique, Indirect; Humans; Mesenchymal Stem Cells; Neoplasm Proteins; Neoplastic Stem Cells; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2012 |
Superior vena cava syndrome as the initial manifestation of thymic carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Etoposide; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Invasiveness; Palliative Care; Prognosis; Radiography; Radiotherapy, Adjuvant; Superior Vena Cava Syndrome; Thymus Neoplasms; Vena Cava, Superior | 2012 |
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Cell Cycle; Colonic Neoplasms; Etoposide; Humans; Staurosporine; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carcinoma; Carrier Proteins; Caspases; Cell Survival; Cytochrome c Group; Etoposide; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Glycoproteins; Mitochondrial Proteins; Models, Biological; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carcinoma; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Epstein-Barr Virus Nuclear Antigens; Etoposide; Female; G2 Phase; Genetic Therapy; Humans; Kinetics; Mitosis; Ovarian Neoplasms; Paclitaxel; Receptor, ErbB-2; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2003 |
Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thymus Neoplasms; Treatment Outcome; Vincristine | 2003 |
Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells.
Topics: Animals; Antigens, CD; Blotting, Western; Carcinoma; Cell Line, Tumor; Etoposide; Female; Fluorescent Antibody Technique, Indirect; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Kangai-1 Protein; Liver; Male; Membrane Glycoproteins; Mice; Mice, Nude; Microscopy, Confocal; Nucleic Acid Synthesis Inhibitors; Precipitin Tests; Proteins; Proto-Oncogene Proteins; RNA, Messenger; Spleen; Tumor Suppressor Protein p53 | 2003 |
[Morphological findings after moving beam irradiation of esophagus carcinoma].
Topics: Carcinoma; Carmustine; Esophageal Neoplasms; Etoposide; Humans; Radiotherapy | 1957 |
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gastrectomy; Gastric Mucosa; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Probability; Prognosis; Risk Assessment; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA Repair; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Irinotecan; Luciferases; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
Adrenal carcinoma treated with chemotherapy can result in prolonged survival.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cushing Syndrome; Etoposide; Female; Humans; Middle Aged; Survival Analysis | 2004 |
Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carrier Proteins; Caspases; Cell Line, Tumor; Cell Membrane; Cytochromes c; DNA Fragmentation; Down-Regulation; Etoposide; HeLa Cells; High-Temperature Requirement A Serine Peptidase 2; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Potentials; Mitochondria; Mitochondrial Proteins; Peptides; Protein Transport; Proteins; RNA, Small Interfering; Serine Endopeptidases | 2004 |
[A case of gastric endocrine cell carcinoma with neck lymph node metastasis resected after neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Neck; Stomach Neoplasms | 2004 |
Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Child, Preschool; Choroid Plexus Neoplasms; Cyclophosphamide; Etoposide; Female; Humans; Li-Fraumeni Syndrome; Magnetic Resonance Imaging; Neoplasm Metastasis | 2005 |
Colonic T-cell leukemia mimicking colon carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Colectomy; Colonic Neoplasms; Diagnosis, Differential; Disease Progression; Etoposide; Humans; Leukemia, T-Cell; Male | 2005 |
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Thymoma; Thymus Neoplasms; Treatment Outcome | 2005 |
Images in neuro-oncology: choroid plexus carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Choroid Plexus Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Immunohistochemistry; Infant; Male; Neurosurgical Procedures; Vincristine | 2006 |
Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.
Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Mitotane; Tomography, X-Ray Computed | 2006 |
Carcinoma showing thymus-like element (CASTLE) of thyroid: combined modality treatment in 3 patients with locally advanced disease.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Radiography; Radiotherapy, Adjuvant; Thymus Neoplasms; Thyroid Neoplasms; Thyroidectomy | 2007 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Inhibition of Akt/protein kinase B activity sensitizes moderately- to un-differentiated gastric cancer cells to chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Etoposide; Humans; Proto-Oncogene Proteins c-akt; Stomach Neoplasms | 2007 |
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma; Cisplatin; Etoposide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Prognosis; Radiotherapy, Adjuvant; Survival Analysis; Vincristine | 2008 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Bleomycin; Carcinoma; Cell Count; Cell Culture Techniques; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Gemcitabine; Humans; Thyroid Neoplasms; Tumor Cells, Cultured | 2008 |
Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Proliferation; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Idarubicin; Immunohistochemistry; Male; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2008 |
[Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoid Tumor; Carcinoma; Carcinoma, Neuroendocrine; Cell Differentiation; Etoposide; Female; Follow-Up Studies; Humans; Liver Neoplasms; Rectal Neoplasms; Risk Factors; Treatment Outcome | 2008 |
[Results of drug therapy of inoperable non-small cell lung carcinoma with VP 16-213 (Etoposide) and cis-platin. A phase II study].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1983 |
Small-cell carcinoma of the esophagus: treatment by chemotherapy alone.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Esophageal Neoplasms; Etoposide; Female; Humans; Radiography | 1980 |
[Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Topics: Adenocarcinoma; Body Weight; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Leukocyte Count; Lung Neoplasms; Podophyllotoxin; Vomiting | 1981 |
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma; Cell Division; Cisplatin; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunologic Techniques; In Vitro Techniques; Interleukin-6; Male; Molecular Sequence Data; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 1995 |
Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.
Topics: Abdominal Muscles; Abdominal Neoplasms; Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Combined Modality Therapy; Drug Screening Assays, Antitumor; Etoposide; Female; Fibrinolysin; Glycoproteins; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Specific Pathogen-Free Organisms; Trypsin Inhibitors | 1995 |
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carboplatin; Carcinoma; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged | 1993 |
Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Remission Induction; Survival Rate; Treatment Outcome | 1995 |
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Carcinoma; Chromosome Aberrations; Chromosome Disorders; Cisplatin; Etoposide; Female; Germinoma; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Karyotyping; Lymphoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Unknown Primary; Neuroectodermal Tumors, Primitive, Peripheral; Prospective Studies; Retroperitoneal Neoplasms; Testicular Neoplasms; Treatment Outcome | 1995 |
Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Gene Expression; Humans; Immunoenzyme Techniques; Male; Middle Aged; Peplomycin; Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms | 1994 |
Enhanced therapeutic effects of anti-tumour agents against growth and metastasis of colon carcinoma 26 when given in combination with interferon and interleukin-2.
Topics: Animals; Carcinoma; Cisplatin; Colonic Neoplasms; Drug Therapy, Combination; Etoposide; Interferon-beta; Interleukin-2; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis | 1994 |
Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Remission Induction; Survival Rate | 1994 |
Low-dose oral etoposide in epithelial cancer of the ovary.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Carcinoma; Etoposide; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Remission Induction; Salvage Therapy | 1993 |
Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367.
Topics: Animals; Anti-Infective Agents; Carcinoma; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Superhelical; Drug Screening Assays, Antitumor; Enzyme Induction; Etoposide; Female; Fluoroquinolones; Leukemia L1210; Leukemia P388; Mice; Mice, Inbred Strains; Quinolones; Stereoisomerism; Topoisomerase II Inhibitors | 1993 |
Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinogens; Carcinoma; Cell Adhesion; Down-Regulation; Enzyme Activation; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Male; Melphalan; Phorbol Esters; Prostatic Neoplasms; Protein Kinase C; Tumor Cells, Cultured | 1996 |
Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.
Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Liver Neoplasms; Mitotane | 1996 |
[In vitro chemosensitivity test for seven undifferentiated thyroid carcinoma cell lines using MTT assay].
Topics: Antineoplastic Agents; Bleomycin; Carcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Methotrexate; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Tumor Cells, Cultured; Vincristine | 1996 |
Absence of correlation between chemo- and radioresistance in a range of human tumour cell lines.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Clone Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; HeLa Cells; Humans; Laryngeal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation Tolerance; Selection, Genetic; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vincristine | 1996 |
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Topics: Antineoplastic Agents; Bleomycin; Bryostatins; Carcinoma; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Head and Neck Neoplasms; Herpes Simplex Virus Protein Vmw65; Humans; Lactones; Lung Neoplasms; Macrolides; Ovarian Neoplasms; Paclitaxel; Phorbol 12,13-Dibutyrate; Protein Kinase C; Signal Transduction; Tumor Cells, Cultured | 1996 |
Adequacy of chemotherapy prior to cytoreductive surgery in testicular carcinoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Bone Marrow Transplantation; Carcinoma; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Salvage Therapy; Survival Rate; Testicular Neoplasms; Treatment Failure; Vinblastine | 1996 |
"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms | 1996 |
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Carcinoma; Cell Separation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged | 1997 |
Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma; Cisplatin; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Laparotomy; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Neoplasm Staging; Ovarian Neoplasms; Retroperitoneal Space; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 1997 |
Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bleomycin; Blotting, Western; Carcinoma; Cisplatin; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Genes, MDR; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Proteins; Point Mutation; Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Vincristine | 1997 |
CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Palliative Care; Prognosis; Prospective Studies; Sensitivity and Specificity; Stomach Neoplasms; Treatment Outcome | 1997 |
Undifferentiated carcinoma of the liver with neuroendocrine features: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Cisplatin; Etoposide; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Synaptophysin | 1998 |
Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pelvis; Peritoneal Neoplasms; Prognosis; Survival Rate | 1998 |
A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile.
Topics: Adrenal Cortex Neoplasms; Adult; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Genes, p53; Glucocorticoids; Humans; Male; Mineralocorticoids; Mitotane; Neoplasm Proteins; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Vincristine | 1997 |
Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Injections, Intravenous; Lung Neoplasms; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nitrosourea Compounds; Paclitaxel; Vinblastine | 1998 |
CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma; Cisplatin; Computer Graphics; Computer Simulation; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Interactions; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Models, Biological; Models, Chemical; Software; Tumor Cells, Cultured | 1999 |
Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Division; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microbial Sensitivity Tests; Mutation; Neoplasm Transplantation; Radiation Tolerance; Retroviridae; Transduction, Genetic; Tumor Suppressor Protein p53 | 1999 |
[Intra-abdominal desmoplastic small round-cell tumors. An entity among peritoneal carcinomatoses in young adults].
Topics: Abdominal Neoplasms; Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Fatal Outcome; Humans; Ifosfamide; Male; Middle Aged; Treatment Outcome | 2000 |
Management of patients with cancer of unknown primary site.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma; Etoposide; Evaluation Studies as Topic; Female; Humans; Male; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2000 |
A case of adrenocortical carcinoma associated with recurrence after laparoscopic surgery.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Diagnostic Errors; Dichlorodiphenyldichloroethane; Etoposide; Fatal Outcome; Female; Humans; Laparoscopy; Middle Aged; Neoplasm Seeding | 2000 |
Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzylisoquinolines; Butyrates; Carcinoma; Cell Nucleus; Colonic Neoplasms; Coloring Agents; Cyclic P-Oxides; Cytoplasm; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Microscopy, Fluorescence; Neoplasm Proteins; Nicotinic Acids; RNA, Catalytic; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2001 |
Surgical and combined treatment of gastric cancer--own experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Fluorouracil; Gastrectomy; Guidelines as Topic; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Palliative Care; Stomach Neoplasms; Survival Rate | 2000 |
In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Etoposide; Fluorouracil; Nasopharyngeal Neoplasms; Toxicity Tests; Tumor Cells, Cultured | 2000 |
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin.
Topics: Antineoplastic Agents; Carcinoma; DNA-Binding Proteins; Doxorubicin; Drug Resistance; Etoposide; Gliotoxin; Humans; I-kappa B Proteins; Leupeptins; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Sulfasalazine | 2001 |
Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Topics: Amsacrine; Anion Transport Proteins; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blotting, Northern; Breast Neoplasms; Carcinoma; Carrier Proteins; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Isoenzymes; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 2001 |
Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Topics: Alternative Splicing; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Exons; Humans; Isoenzymes; Phosphorylation; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Carrier Proteins; Caspase 3; Caspase 9; Caspases; Cell Cycle; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Doxorubicin; Etoposide; Female; HeLa Cells; Humans; Microfilament Proteins; Mitochondria; Radiation, Ionizing; Transformation, Genetic; Tumor Cells, Cultured | 2001 |
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; Clone Cells; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Humans; Mitoxantrone; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; RNA, Messenger; RNA, Neoplasm; Selection, Genetic; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vincristine | 2001 |
Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma; Caspases; Etoposide; Genes, bcl-2; Glutathione; Humans; Immunotherapy; Intracellular Fluid; Male; Maleates; Prostatic Neoplasms; Radiotherapy; Sulfhydryl Compounds; Tumor Cells, Cultured; Up-Regulation | 2001 |
Neutrophil-rich Ki-1-positive anaplastic large cell lymphoma: a study by fine-needle aspiration biopsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Infections; Ki-67 Antigen; Lymphocytes, Null; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Recurrence, Local; Neutrophils; Prednisone; Radiotherapy, Adjuvant; T-Lymphocytes; Vincristine | 2002 |
[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Prostatic Neoplasms; Remission, Spontaneous | 1975 |
Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Creatinine; Etoposide; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mitomycins; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 1992 |
The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Clinical Protocols; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Neoplasms, Unknown Primary; Remission Induction; Salvage Therapy; Survival Rate; Vinblastine | 1992 |
Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Remission Induction | 1992 |
Etoposide microcrystals suspended in oil: a new dosage form to peritoneal carcinomatosis in mice.
Topics: Animals; Carcinoma; Chemistry, Pharmaceutical; Etoposide; Injections, Intraperitoneal; Leukemia P388; Male; Mice; Mice, Inbred DBA; Mice, Inbred Strains; Neoplasm Transplantation; Oils; Peritoneal Neoplasms; Suspensions | 1992 |
Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Pilot Projects; Recurrence; Treatment Outcome | 1992 |
Pharmacology of intrathecal VP-16-213 in dogs.
Topics: Animals; Carcinoma; Disease Models, Animal; Dogs; Etoposide; Injections, Spinal; Meningeal Neoplasms | 1992 |
Chemotherapy for pancreaticoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Child, Preschool; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Male; Pancreatic Neoplasms; Teniposide; Vincristine | 1992 |
Carcinoma of unknown primary: identification of a treatable subset?
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary | 1990 |
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma; Cisplatin; Etoposide; Female; Gastrins; Glucagon; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Remission Induction; Survival Rate | 1991 |
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1991 |
Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Infusions, Parenteral; Ovarian Neoplasms; Remission Induction; Survival Analysis; Thiosulfates; Time Factors | 1990 |
A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms | 1990 |
Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Time Factors | 1985 |
Chemotherapy for thyroid cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Thyroid Neoplasms; Vincristine | 1987 |
Case report of successful use of VP-16 in nasopharyngeal carcinoma.
Topics: Adolescent; Carcinoma; Etoposide; Humans; Male; Nasopharyngeal Neoplasms; Patient Compliance; Remission Induction | 1989 |
Advanced gastric cancer: a new combined surgical and oncological approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Methotrexate; Middle Aged; Reoperation; Stomach Neoplasms | 1989 |
First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms | 1989 |
Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Topics: Administration, Oral; Biological Availability; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Hodgkin Disease; Humans; Injections, Intravenous; Kinetics; Lung Neoplasms; Lymphoma; Male; Neoplasms; Podophyllotoxin | 1986 |
Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the Groupe Franais Pneumo-Cancérologie.
Topics: Adenocarcinoma; Aged; Brain; Brain Neoplasms; Carcinoma; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Tomography, X-Ray Computed | 1988 |
Cisplatin plus VP 16-213 in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma; Cisplatin; Depression, Chemical; Drug Evaluation; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Time Factors | 1988 |
Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Epithelium; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms | 1987 |
Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Vaginal Neoplasms; Vulvar Neoplasms | 1987 |
Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detection.
Topics: Carcinoma; Chromatography, High Pressure Liquid; Electrochemistry; Etoposide; Female; Humans; Indicators and Reagents; Ovarian Neoplasms; Podophyllotoxin; Teniposide; Time Factors | 1986 |
Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16).
Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Mitotane; Neoplasm Metastasis | 1986 |
Cisplatin plus VP16-213 in refractory ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ovarian Neoplasms | 1987 |
Chemotherapy of invasive carcinoma of the bladder.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Humans; Lymphatic Metastasis; Methotrexate; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 1985 |
Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Vindesine | 1986 |
Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Topics: Administration, Oral; Aged; Carcinoma; Cisplatin; Cystadenocarcinoma; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Middle Aged; Nausea; Ovarian Neoplasms; Podophyllotoxin; Vomiting | 1985 |